The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of human immunodeficiency virus (HIV)-positive pregnant women in the UK. The scope includes guidance on the use of antiretroviral therapy (ART) both to prevent HIV mother-to-child transmission (MTCT) and for the welfare of the mother herself, guidance on mode of delivery and recommendations in specific patient populations where other factors need to be taken into consideration, such as co-infection with other agents. The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of pregnant women with HIV infection.
The purpose of the 2014 interim review is to identify significant developments that would either lead to a change in recommendation or a change in the strength of recommendation. These changes and the supporting evidence are highlighted. More detail has been added in areas of controversy. New data that simply support the existing data have not routinely been included in this revision.
Presentation on these guidelines is available to download and use to facilitate dissemination and implementation of the BHIVA guidance.
Download the PDF
Download the Powerpoint Presentation
Dr Annemiek de Ruiter, Dr Graham P Taylor, Ms Polly Clayden, Dr Jyoti Dhar, Mrs Kate Gandhi, Dr Yvonne Gilleece, Dr Kate Harding, Dr Phillip Hay, Ms Jane Kennedy, Dr Naomi Low-Beer, Dr Hermione Lyall, Dr Adrian Palfreeman, Dr Siobhan O'Shea, Dr Pat Tookey, Ms Jennifer Tosswill, Dr Steven Welch, Dr Ed Wilkins
The guidelines will be fully updated and revised in 2017. In the meantime, the Writing Group will continue to confer regularly to consider new information and, where this is thought to be clinically important, amendments and addendums to the current recommendations will be published prior to the full revision date.
HIV Medicine (2014), 15 (Suppl. 5), 1–77.